文献速递真实世界研究与卫生经济流行病学与生物统计

澳大利亚临床试验中同步开展卫生经济学评价的采用情况:一项观察性研究

Uptake of health economic evaluations alongside clinical trials in Australia: an observational study.
PubMed 文献 · Trials · 2024-10-22

该观察性研究通过注册库描述性分析、澳大利亚临床试验联盟(ACTA)网络横断面调查及急性期试验亚组分析,评估澳大利亚主导临床试验同步提出卫生经济学评价的比例,并分析其与试验特征的关系。结果显示,9251项随机试验中仅11%提出卫生经济学评价,ACTA网络试验为43%(227项中),急性期试验亚组为22%(324项中)、ACTA网络急性期试验为53%(38项中);校正后政府资助的急性期试验较医院、大学及其他资助者更可能提出并发表卫生经济学评价。

要点

  • 澳大利亚主导随机试验中仅11%(9251项中)提出卫生经济学评价,ACTA网络试验为43%(227项中)。
  • 急性期试验亚组中22%(324项中)提出卫生经济学评价,ACTA网络急性期试验为53%(38项中)。
  • 校正后政府资助的急性期试验较其他资助者更可能提出并发表卫生经济学评价。

核心结论

  • 当前澳大利亚主导临床试验同步开展卫生经济学评价的采用率低,ACTA网络试验子集采用率较高。
  • 作者认为存在重要机会将卫生经济学评价嵌入临床试验(尤其3期试验),以增加研究产出并优化研究转化。
  • 作者认为投资支持卫生经济学家或卫生经济学评价经费的临床试验网络,可能是提高同步开展卫生经济学评价采用率的有效策略。

研究设计与样本

  • 观察性研究,包括临床试验注册库的描述性分析、对澳大利亚临床试验联盟(ACTA)网络的横断面调查,以及已完成急性期试验的亚组分析。
  • 采用逻辑回归识别急性期试验提出并随后发表卫生经济学评价的预测因素。

主要发现

  • 9251项澳大利亚主导随机临床试验中11%提出卫生经济学评价。
  • 227项ACTA网络试验中43%提出卫生经济学评价。
  • 324项急性期试验中22%提出卫生经济学评价,38项ACTA网络急性期试验中53%提出卫生经济学评价。
  • 校正分期、注册年份、主要申办者类型和对照后,政府机构资助的急性期试验较医院、大学和其他资助者资助的试验更可能提出并发表卫生经济学评价。

临床怎么用

  • 作者认为投资支持卫生经济学家或卫生经济学评价经费的临床试验网络,可能是提高同步开展卫生经济学评价采用率的有效策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Australia's clinical trials sector is highly productive with continued sector investment needed to enhance research impact. Generating economic evidence alongside trials has the potential to facilitate the implementation of trial results into practice. Ascertaining the use of health economic evaluations alongside clinical trials can assist in determining whether clinical trials fully realize and operationalize their potential to change policy and practice. The aims of this study were to ascertain the uptake of health economic evaluations alongside Australian-led clinical trials and explore associations between uptake and trial characteristics. METHODS: This observational study comprised a descriptive analysis of clinical trials registries, a cross-sectional survey of Australian Clinical Trials Alliance (ACTA) networks, and a subgroup analysis of completed acute care trials. Descriptive analyses of trial registrations were conducted, with logistic regressions used to identify predictors of proposing and subsequently publishing a health economic evaluation alongside acute care trials. RESULTS: Few randomized Australian-led clinical trials (11% of 9251) and ACTA network trials (43% of 227) proposed a health economic evaluation. In the subgroup analysis, 22% of the 324 acute care trials and 53% of the 38 ACTA network acute care trials proposed a health economic evaluation. Acute care trials funded by government bodies were significantly more likely to propose and publish a health economic evaluation than those funded by hospitals, universities, and other funders, after adjusting for phase, registration year, primary sponsor type, and comparator. CONCLUSIONS: Current uptake of health economic evaluations alongside Australian-led clinical trials is low, with uptake higher among the subset of ACTA network trials. This is despite economic evidence playing an increasingly prominent role in health system management, as well as rising health expenditure, limited budgets, and competing demands. There is significant opportunity to embed health economic evaluations alongside clinical trials, particularly phase 3 trials, to increase research outputs and optimize research translation. Investing in clinical trial networks that support funding for a health economist or a health economic evaluation may be an effective strategy to increase the uptake of health economic evaluations alongside trials.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Carrandi A, Wells C, Morton RL, et al. Uptake of health economic evaluations alongside clinical trials in Australia: an observational study. Trials. 2024. PMID: 39434149. doi:10.1186/s13063-024-08562-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。